Regeneron Q2 2026 revenue up 17% to $4.3B; non-GAAP EPS $14.29 beats; Dupixent sales up 38%

REGENERON PHARMACEUTICALS, INC.

Total revenues $4.291B (+17% YoY); GAAP EPS $12.23 (incl. $1.02 IPR&D charge); non-GAAP EPS $14.29 (+11%).
Dupixent global net sales (Sanofi) up 38% to $6.0B; EYLEA HD U.S. net sales up 52% to $596M; Libtayo global up 30% to $489M.
Sanofi Development Balance fully repaid; collaboration profits to step up in Q3. Guidance raised: GAAP gross margin 78-79% (prior 77-78%).
Cemdisiran NDA accepted for gMG with priority review; FDA target action date Nov 2026.
Share repurchases $1.2B in Q2; $2.0B in H1; dividend $0.94/share declared.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.